Jack P McNulty

  • Citations Per Year
Learn More
The nonnarcotic nonaddictive neuropathic pain reliever ketamine, which was synthesized in the early 1960s by Parke-Davis, was first administered to human patients in 1965. Used by the U. S. military as a field anesthetic during the Vietnam War, it slowly became popular as both an induction and maintenance agent for the general anesthesia required during(More)
BACKGROUND Levorphanol has been reported to provide analgesia at doses that suggest it does not act like other pure agonist opioids. A dual effect of action on both opioid receptors and n-methyl, d-aspartate (NMDA) receptors has been proposed to be responsible for this effect. METHOD Case series of patients treated with levorphanol when pain did not(More)
In the United States the most common cancers of the head and neck are those of the oral cavity and pharynx. In 2007, oral cancer will be diganosed in more than 37,000 Americans and will claim more than 7,500 lives. The report presented here describes a case of extrarodinary pain in a woman with metastatic adenocarcinoma of the hard palate. At the time of(More)
Severe chronic neuropathic pain, which can profoundly and negatively affect quality of life, is usually caused by damage to peripheral nerve tissue from various physical, thermal, or chemical agents and is difficult to relieve. Commonly used opioids are quite effective in relieving nociceptive pain, but nerves that are damaged send pain-sensing fibers into(More)
The search for an effective and affordable treatment for severe chronic pain, particularly neuropathic pain, has been elusive. The reluctance of many physicians to prescribe strong opioids for pain when other modalities have failed has resulted in the undertreatment of many patients. Levorphanol is 1 of 2 opioids that block N-methyl-D-aspartate receptors.(More)
  • 1